Brickell Stock Today

BBI -  USA Stock  

USD 0.18  0.01  5.26%

Market Performance
0 of 100
Odds Of Distress
Over 52
Brickell Biotech is trading at 0.18 as of the 17th of May 2022. This is a -5.26 percent decrease since the beginning of the trading day. The stock's open price was 0.19. Brickell Biotech has 52 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Brickell Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of May 2020 and ending today, the 17th of May 2022. Please note, there could be an existing legal relationship between Brickell Biotech (BBI) and Blockbuster (BLIAQ). Click here to learn more.
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. The company has 115.05 M outstanding shares of which 4.21 M shares are currently shorted by investors with about 0.54 days to cover. More on Brickell Biotech

Brickell Biotech Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Brickell Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Brickell Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Brickell Biotech generated a negative expected return over the last 90 days
Brickell Biotech has high historical volatility and very poor performance
Brickell Biotech has some characteristics of a very speculative penny stock
Brickell Biotech has high likelihood to experience some financial distress in the next 2 years
Brickell Biotech was previously known as BRICKELL BIOTECH INC and was traded on NASDAQ Exchange under the symbol VICL.
The company reported the last year's revenue of 404 K. Reported Net Loss for the year was (39.47 M) with loss before taxes, overhead, and interest of (27.83 M).
Brickell Biotech has about 26.88 M in cash with (36.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Brickell Biotech has a frail financial position based on the latest SEC disclosures
Latest headline from seekingalpha.com: Brickell Biotech stock surges postmarket on sale of rights to sofpironium bromide - Seeking Alpha
Brickell Biotech Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Brickell Biotech SEC Filings
Brickell Biotech SEC Filings Security & Exchange Commission EDGAR Reports
Older SymbolVICL
New SymbolBBI1
Related EntityBLIAQ (Blockbuster)
President CEO, DirectorGarth Braun  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Brickell Biotech report their recommendations after researching Brickell Biotech's financial statements, talking to executives and customers, or listening in on Brickell Biotech's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Brickell Biotech. The Brickell consensus assessment is calculated by taking the average forecast from all of the analysts covering Brickell Biotech.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Brickell Biotech based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Brickell Biotech financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares86.7 M80.3 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted86.7 M80.3 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations(37.1 M)(36.1 M)
Fairly Down
Decreasing
Slightly volatile
Total Assets37.2 M29.7 M
Significantly Up
Decreasing
Slightly volatile
Total Liabilities4.9 M4.8 M
Fairly Up
Increasing
Very volatile
Current Assets35 M29.6 M
Fairly Up
Decreasing
Slightly volatile
Current Liabilities7.3 M4.8 M
Way Up
Increasing
Stable
Total Debt403.6 K393.3 K
Fairly Up
Decreasing
Slightly volatile
Gross Margin0.931.15
Significantly Down
Increasing
Slightly volatile
Asset Turnover0.01330.013
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Brickell Biotech's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Financial Strength
Brickell Biotech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Brickell Biotech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Brickell Biotech's financial leverage. It provides some insight into what part of Brickell Biotech's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Brickell Biotech's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Brickell Biotech deploys its capital and how much of that capital is borrowed.
Liquidity
Brickell Biotech cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 69 K in debt with debt to equity (D/E) ratio of 0.0, which may show that the company is not taking advantage of profits from borrowing. Brickell Biotech has a current ratio of 6.03, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Brickell Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Brickell Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Brickell Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Brickell to invest in growth at high rates of return. When we think about Brickell Biotech's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(37.1 Million)Share
Brickell Biotech (BBI) is traded on NASDAQ Exchange in USA. It is located in 5777 Central Avenue and employs 16 people. Brickell Biotech was previously known as BRICKELL BIOTECH INC and was traded on NASDAQ Exchange under the symbol VICL. Brickell Biotech is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with total capitalization of 20.71 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Brickell Biotech's market, we take the total number of its shares issued and multiply it by Brickell Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Brickell Biotech runs under null sector within null industry. The entity has 115.05 M outstanding shares of which 4.21 M shares are currently shorted by investors with about 0.54 days to cover. Brickell Biotech has about 26.88 M in cash with (36.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Brickell Biotech Probability Of Bankruptcy
Ownership
Brickell Biotech holds a total of one hundred fifteen million fifty thousand outstanding shares. Almost 81.0 percent of Brickell Biotech outstanding shares are held by regular investors with 1.31 (percent) owned by insiders and only 17.27 % by other corporate entities. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Brickell Ownership Details

Brickell Stock Price Odds Analysis

What are Brickell Biotech's target price odds to finish over the current price? In reference to a normal probability distribution, the odds of Brickell Biotech jumping above the current price in 90 days from now is roughly 96.0%. The Brickell Biotech probability density function shows the probability of Brickell Biotech stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 2.169 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Brickell Biotech will likely underperform. Additionally, the company has an alpha of 0.2117, implying that it can generate a 0.21 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 0.18HorizonTargetOdds Above 0.18
3.50%90 days
 0.18 
96.48%
Based on a normal probability distribution, the odds of Brickell Biotech to move above the current price in 90 days from now is roughly 96.0 (This Brickell Biotech probability density function shows the probability of Brickell Stock to fall within a particular range of prices over 90 days) .

Brickell Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Brickell Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Brickell Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Brickell Biotech's value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares3.1 M832 K
Renaissance Technologies LlcCommon Shares1.4 M380 K
Concourse Financial Group Securities IncPut Options0.00.0
Concourse Financial Group Securities IncCall Options0.00.0
View Brickell Biotech Diagnostics

Brickell Biotech Historical Income Statement

Brickell Biotech Income Statement is one of the three primary financial statements used for reporting Brickell's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Brickell Biotech revenue and expense. Brickell Biotech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Brickell Biotech Interest Expense is most likely to decrease significantly in the upcoming years. The last year's value of Interest Expense was reported at 62,100. The current Revenues is estimated to increase to about 414.6 K, while Consolidated Income is projected to decrease to (40.5 M). View More Fundamentals

Brickell Stock Against Markets

Picking the right benchmark for Brickell Biotech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Brickell Biotech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Brickell Biotech is critical whether you are bullish or bearish towards Brickell Biotech at a given time.

Similar Equity Warning - BBI

Brickell Biotech was forked

The entity Brickell Biotech with a symbol BBI was recently forked. You can potentially use BARNETT BANKS INC with a symbol BBI1 from now on.

Brickell Biotech Corporate Executives

Elected by the shareholders, the Brickell Biotech's board of directors comprises two types of representatives: Brickell Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brickell. The board's role is to monitor Brickell Biotech's management team and ensure that shareholders' interests are well served. Brickell Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brickell Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.

Investing Brickell Biotech

You need to understand the risk of investing before taking a position in Brickell Biotech. The danger of trading Brickell Biotech is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Brickell Biotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Brickell Biotech. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Brickell Biotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.